CA-XSOLLA/GDC
21.3.2022 12:02:11 CET | Business Wire | Press release
Xsolla , a global video game commerce company, is attending and presenting at GDC (Game Developers Conference) , the biggest game conference in the world, today through March 25th in San Francisco, California, USA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005435/en/
Xsolla is hosting six informative speaking sessions on Tuesday, March 22nd, including a keynote from President Chris Hewish. Additionally, Xsolla is exhibiting at Moscone South S657, starting on Wednesday, March 23rd, where attendees can meet with Xsolla experts and get a preview of the latest products and solutions designed to accelerate video game commerce in 2022.
“I’m excited to return to GDC in person and to kick off Xsolla’s series of trending topic speaker sessions,” Hewish said. “It’s great to see old friends and meet new people from all over the world who share our passion for video games.”
The Xsolla team is sharing industry updates and their expertise on the tools and services available for video game developers and publishers. Topics will range from mobile game monetization outside of the app store, payments for the enterprise , and token-based systems for digital content with a new NFT Checkout to emerging market opportunities and prelaunch funding . Video-on-demand of the sessions will be available later in the week for those who could not attend to watch and learn.
Tuesday, March 22 | 9:30am - 10:30am [Add to iCal
]
GOING GLOBAL, STAYING LOCAL: HELPING GAME DEVELOPERS SUCCEED
Great games don’t just appear. They start as ideas, and only through the curiosity, dedication, and grit of people all over the globe do they come to life. Xsolla President Chris Hewish outlines ways to ensure that every developer has the same opportunity to see their game become a part of how we play.
Tuesday, March 22 | 10:50am - 11:50am [Add to iCal
]
INSIDE THE WALLED PAYMENT GARDEN: A GUIDE TO MOBILE MARKET FREEDOM
In this session, Anthony Mendoza and Miikka Luotio share a frank discussion on how developers can break into mobile gaming's 'walled payment garden' and grow their games just as many others have already done.
Tuesday, March 22 | 1:20pm - 1:50pm [Add to iCal
]
GAME OF FUNDS: SUCCESS IS COMING
Xsolla’s dynamic duo of funding, Justin Berenbaum and Lily Goldner, host special guests David Martinez from Raw Fury and Ken Seto from Massive Damage Games in a fireside chat, where you’ll discover how to improve your chances and create business alliances.
Tuesday, March 22 | 2:10pm - 2:40pm [Add to iCal
]
BEYOND CREDIT: TAKING ADVANTAGE OF EMERGING PAYMENT METHODS
WORLDWIDE
"Cash, check or charge?" It used to be that these were the only options when handling payments. Now there are hundreds. Berkley Egenes leads a team of Xsolla regional experts as they discuss how to control the chaos and take advantage of emerging payment methods around the globe.
Tuesday, March 22 | 3:00pm - 3:30pm [Add to iCal
]
"THINGS I WISH I KNEW SOONER" ABOUT THE GAME INDUSTRY
Xsolla's Sam Gaglani hosts a panel of games industry pros, including Kara Bilkiss from Rogue Games, Michael Lewis from Take-Two Interactive, and Andreea Enache from Secret Society Games who've "been there, done that" as they share their wisdom and insights. They will focus on topics that affect developers at any studio and discuss things they wish they had known sooner about working in the industry.
Tuesday, March 22 | 3:50pm - 4:20pm [Add to iCal
]
HYBRID TIMES: GAME DEVELOPERS SOUND OFF ON WORKING FROM HOME, COMPENSATION, AND CAREER
The industry-leading platform 80 Level asked the gaming community about recent challenges and opportunities, and over 800 game developers shared their experiences. Kirill Tokarev, Editor in Chief at 80 Level, highlights what these responses reveal about our past and what the future has in store.
Book a meeting with Xsolla’s global game commerce experts to discover how they can help expand your video game commerce in the changing games industry.
For more information on how to attend speaking sessions and connect with Xsolla at GDC 2022, visit https://xsolla.com/gdc2022
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world to support major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information and to learn more, please visit xsolla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom